Aldeyra Therapeutics, Inc. (ALDX) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ALDX Insider Trading Activity
ALDX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $4,955,288 | 3 | 100 |
Related Transactions
| Greenberg Bruce | See Remarks | 0 | $0 | 1 | $51,313 | $-51,313 |
| Machatha Stephen | Chief Development Officer | 0 | $0 | 1 | $75,975 | $-75,975 |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 0 | $0 | 1 | $4.83M | $-4.83M |
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Insider Activity of Aldeyra Therapeutics, Inc.
Over the last 12 months, insiders at Aldeyra Therapeutics, Inc. have bought $0 and sold $4.96M worth of Aldeyra Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aldeyra Therapeutics, Inc. have bought $20.46M and sold $5.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 37,712 shares for transaction amount of $178,755 was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2024‑04‑05.
List of Insider Buy and Sell Transactions, Aldeyra Therapeutics, Inc.
| 2025-04-03 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 3.4M 5.6943% | $1.42 | $4.83M | +54.58% | |
| 2024-08-12 | Sale | Machatha Stephen | Chief Development Officer | 16,041 0.0272% | $4.74 | $75,975 | +11.37% | |
| 2024-08-12 | Sale | Greenberg Bruce | See Remarks | 10,834 0.0184% | $4.74 | $51,313 | +11.37% | |
| 2024-04-05 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 37,712 0.0643% | $4.74 | $178,755 | +6.46% | ||
| 2024-04-04 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 140,281 0.2374% | $4.67 | $655,112 | +7.26% | ||
| 2024-04-03 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 309,847 0.5185% | $4.09 | $1.27M | +20.96% | ||
| 2024-04-02 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 186,051 0.3061% | $3.44 | $640,015 | +41.41% | ||
| 2024-04-01 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 8,374 0.0141% | $3.25 | $27,216 | +53.52% | ||
| 2024-03-12 | Sale | Brady Todd C | President and CEO | 85,324 0.147% | $3.05 | $260,238 | +62.13% | |
| 2024-03-12 | Sale | Machatha Stephen | Chief Development Officer | 11,537 0.0206% | $3.16 | $36,503 | +62.13% | |
| 2024-03-11 | Sale | Brady Todd C | President and CEO | 97,914 0.1675% | $3.27 | $320,521 | +49.85% | |
| 2024-03-11 | Sale | Machatha Stephen | Chief Development Officer | 18,231 0.0324% | $3.41 | $62,102 | +49.85% | |
| 2024-03-11 | Sale | Greenberg Bruce | See Remarks | 13,201 0.0235% | $3.41 | $44,968 | +49.85% | |
| 2023-10-18 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 306,499 0.5276% | $1.74 | $533,308 | +112.14% | |
| 2023-10-16 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 2.45M 3.6657% | $1.60 | $3.92M | +98.63% | |
| 2023-04-12 | Miller-Rich Nancy | director | 509 0.0009% | $10.13 | $5,156 | -45.04% | ||
| 2022-08-09 | EDELMAN JOSEPH | 15,000 0.027% | $7.85 | $117,750 | -4.83% | |||
| 2022-08-08 | EDELMAN JOSEPH | 97,000 0.1669% | $7.24 | $702,280 | -1.53% | |||
| 2022-08-05 | EDELMAN JOSEPH | 141,000 0.2422% | $6.95 | $979,950 | +2.46% | |||
| 2022-08-04 | EDELMAN JOSEPH | 95,100 0.1609% | $6.17 | $586,767 | +13.62% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 5875851 9.8102% | $12.69M | 18 | 3 | +10.5% |
| Machatha Stephen | Chief Development Officer | 236771 0.3953% | $511,425.36 | 0 | 3 | |
| Greenberg Bruce | See Remarks | 126382 0.211% | $272,985.12 | 0 | 2 | |
| EDELMAN JOSEPH | 11350085 18.9498% | $24.52M | 9 | 0 | +19.39% | |
| Brady Todd C | President and CEO | 1471298 2.4564% | $3.18M | 11 | 2 | +8.57% |
| DOUGLAS RICHARD | director | 125000 0.2087% | $270,000.00 | 7 | 0 | +43% |
| Reed Joshua | Chief Financial Officer | 35774 0.0597% | $77,271.84 | 1 | 0 | +5.74% |
| JOYCE MARTIN JOSEPH | 23967 0.04% | $51,768.72 | 5 | 0 | +39.89% | |
| Bronstein Ben | director | 18644 0.0311% | $40,271.04 | 3 | 0 | +4.27% |
| Clark David J | Chief Medical Officer | 17878 0.0298% | $38,616.48 | 1 | 0 | +8.52% |
| Clarke C. Boyd | director | 15500 0.0259% | $33,480.00 | 2 | 0 | +69.28% |
| Phillips Gary M. | director | 9375 0.0157% | $20,250.00 | 1 | 0 | +20.83% |
| TREU JESSE I | director | 8763 0.0146% | $18,928.08 | 0 | 1 | |
| Walker Neal | director | 6250 0.0104% | $13,500.00 | 1 | 0 | +20.83% |
| McMullin David | Chief Commerical Officer | 6148 0.0103% | $13,279.68 | 1 | 0 | +5.74% |
| Tulipano Stephen J | Chief Financial Officer | 3333 0.0056% | $7,199.28 | 1 | 0 | +0.98% |
| Miller-Rich Nancy | director | 922 0.0015% | $1,991.52 | 2 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$3,058,277 | 75 | -5.80% | $129.28M | |
Aldeyra Therapeutics, Inc. (ALDX) | $87,639,490 | 62 | 18.37% | $129.37M |
$79,019,806 | 27 | 7.24% | $126.78M | |
$6,915,275 | 21 | -32.61% | $123.08M | |
$294,424,120 | 20 | 1.33% | $122.66M | |
$448,999,793 | 15 | -19.99% | $123.47M | |
$4,701,608 | 14 | -4.34% | $132.94M | |
$91,870,774 | 13 | 3.64% | $169.99M | |
$10,143,329 | 12 | 11.84% | $122.92M | |
$2,788,839 | 12 | 6.73% | $127.48M | |
$15,799,576 | 12 | -39.47% | $171.86M | |
$145,194 | 11 | -27.37% | $125.31M | |
$18,262,420 | 10 | 29.82% | $162.59M | |
$9,999,920 | 10 | -40.03% | $141.89M | |
$6,593,243 | 8 | 12.72% | $126.41M | |
$17,675,244 | 7 | 92.20% | $168.27M | |
$63,981 | 5 | -11.55% | $149.43M | |
$88,549,962 | 5 | -16.91% | $159.36M | |
$149,309 | 3 | 6.07% | $176.19M |
ALDX Institutional Investors: Active Positions
| Increased Positions | 59 | +46.09% | 4M | +10.53% |
| Decreased Positions | 48 | -37.5% | 3M | -8.9% |
| New Positions | 23 | New | 2M | New |
| Sold Out Positions | 18 | Sold Out | 877,371 | Sold Out |
| Total Postitions | 139 | +8.59% | 37M | +1.63% |
ALDX Ownership Change vs Market
Institutional Investor Ownership
| Perceptive Advisors Llc | $26,065.00 | 15.46% | 9.28M | 0 | 0% | 2024-12-31 |
| Knoll Capital Management, Llc | $15,386.00 | 9.13% | 5.48M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $10,557.00 | 6.26% | 3.76M | -3,831 | -0.1% | 2024-12-31 |
| Blackrock, Inc. | $10,498.00 | 6.23% | 3.74M | -54,152 | -1.43% | 2025-03-31 |
| Kennedy Capital Management Llc | $4,127.00 | 2.45% | 1.47M | -412,559 | -21.93% | 2024-12-31 |
| Ardsley Advisory Partners Lp | $3,232.00 | 1.92% | 1.15M | +650,000 | +130% | 2024-12-31 |
| Geode Capital Management, Llc | $3,146.00 | 1.87% | 1.12M | +4,927 | +0.44% | 2024-12-31 |
| State Street Corp | $2,904.00 | 1.72% | 1.03M | +59,465 | +6.11% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $2,067.00 | 1.23% | 735,763 | +131,722 | +21.81% | 2024-12-31 |
| Raymond James Financial Inc | $2,043.00 | 1.21% | 727,118 | +727,118 | New | 2024-12-31 |